Arena Pharmaceuticals (ARNA) Volatile as FDA Minutes from May 10 Panel Posted
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Trader chatter on Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) is picking up after biotech watcher Adam Feuerstein of the Street.com notes that minutes from the May 10th FDA panel on lorcaserin have been posted.
He notes on Twitter, "The approved FDA panel minutes don't show lorcaserin in such a nice light. Many panelists "reluctantly voted yes..."
Investors are waiting on the 6/27 PDUFA date for drug approval.
Link to minutes and other material.
He notes on Twitter, "The approved FDA panel minutes don't show lorcaserin in such a nice light. Many panelists "reluctantly voted yes..."
Investors are waiting on the 6/27 PDUFA date for drug approval.
Link to minutes and other material.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA accepts Merck's sBLA for Enflonsia to cover second RSV season
- DP World acquires six UK grocery logistics sites from GXO
- Arrowhead buys FDA priority review voucher for plozasiran sNDA
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
